Cat. No.: HY-181929

RAI-20

(Synonyms: H018)

Customer Review

Based on 1 Customer Validation

RAI-20 (H018) is an orally active JAK1/JAK2 dual inhibitor (IC₅₀=15.1 and 22.7 nM). RAI-20 exhibits excellent pharmacokinetic properties, including plasma stability, systemic exposure, and a long half-life. In a collagen-induced arthritis rat model, RAI-20 shows significant anti-inflammatory and anti-arthritic activities, effectively reducing paw swelling volume and arthritis index. RAI-20 can be used for research on the pathogenesis of rheumatoid arthritis.

For research use only. We do not sell to patients.

Purity: 98.66%
CAS No.: 2549180-90-5
Formula: C₂₀H₂₁FN₄O₃S₂
Molecular Weight:448.53

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

RAI-20 Chemical Structure

CAS No.: 2549180-90-5

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target

JAK2

22.7 nM (IC₅₀)

JAK1

15.1 nM (IC₅₀)

All JAK Isoforms :

In Vitro

RAI-20 (3×10^- serial dilutions; under standard cell culture conditions) potently inhibits Ba/F3 cell proliferation with an IC₅₀ of 1.21 μM^[1].
RAI-20 (serial dilutions; 10 min compound pre-incubation, 10 min IL-6 stimulation) inhibits IL-6-induced pSTAT1 expression in human whole blood cells with an IC₅₀ of 1.45 μM^[1].
RAI-20 (up to 10 μM (CYP inhibition), serial dilutions (other assays); incubated to measure T_1/2 (plasma stability, hepatic microsomal stability)) exhibits favorable in vitro pharmacokinetic properties including prolonged human plasma stability, moderate hepatic microsomal metabolism, high plasma protein binding, no significant CYP inhibition, and hERG inhibition with an IC₅₀ of 11.5 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

Ba/F3 cell
Concentration:

3x serial dilutions
Incubation Time:

under standard cell culture conditions
Result:

Inhibited Ba/F3 cell proliferation with an IC₅₀ of 1.21 μM.

Parmacokinetics

Species	Dose	Route	T_1/2	T_max	C_max	AUC	AUC_0-∞
Rat^[1]	5 mg/kg	p.o.	3.06 h	0.92 h	527.64 ng/mL	/	3432.96 ng·h/mL
Rat^[1]	10 mg/kg	p.o.	7.4 h	1.0 h	2402.5 ng/mL	10941.5 ng·h/mL	/

In Vivo

RAI-20 (2-10 mg/kg; p.o.; daily; 14 days) elicits potent, dose-dependent anti-arthritic activity in Lewis rats with collagen-induced arthritis, with the 10 mg/kg daily oral dose producing the greatest reductions in hind paw volume and arthritis index^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Lewis rats (immunized with type II collagen intradermally at the base of the tail on day 0, followed by a booster immunization on day 7)^[1]
Dosage:

2 mg/kg; 3 mg/kg; 5 mg/kg; 10 mg/kg
Administration:

p.o.; daily; 14 days
Result:

Exhibited dose-dependent reductions in arthritis index, with scores of 8.63, 9.25, 8.00, and 7.25 for the 2 mg/kg, 3 mg/kg, 5 mg/kg, and 10 mg/kg doses, respectively.
Showed lower hind paw volume (3.826 ± 0.075 cm³ at day 28) and arthritis index at every time point from day 17 to day 28 in the 10 mg/kg group compared to other control drugs.
Demonstrated a trend of body weight recovery in all dose groups during days 24-28.

Chemical Information

CAS No. 2549180-90-5
Appearance Solid
Molecular Weight 448.53
Formula C₂₀H₂₁FN₄O₃S₂
SMILES

O=C([C@H]1[C@H](F)C1)NC2=CN3C(C4=CC=C(CN5CCS(CC5)(=O)=O)S4)=CC=CC3=N2
Synonyms

H018
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (111.48 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2295 mL

11.1475 mL

22.2951 mL

5 mM

0.4459 mL

2.2295 mL

4.4590 mL

10 mM

0.2230 mL

1.1148 mL

2.2295 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Portuguese - PT (254 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Zhu H, et al. Discovery of selective JAK1/2 inhibitor H018, a phase II agent with demonstrated preclinical anti-rheumatoid arthritis activity. Eur J Med Chem. Published online March 2, 2026. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2295 mL	11.1475 mL	22.2951 mL	55.7376 mL
	5 mM	0.4459 mL	2.2295 mL	4.4590 mL	11.1475 mL
	10 mM	0.2230 mL	1.1148 mL	2.2295 mL	5.5738 mL
	15 mM	0.1486 mL	0.7432 mL	1.4863 mL	3.7158 mL
	20 mM	0.1115 mL	0.5574 mL	1.1148 mL	2.7869 mL
	25 mM	0.0892 mL	0.4459 mL	0.8918 mL	2.2295 mL
	30 mM	0.0743 mL	0.3716 mL	0.7432 mL	1.8579 mL
	40 mM	0.0557 mL	0.2787 mL	0.5574 mL	1.3934 mL
	50 mM	0.0446 mL	0.2230 mL	0.4459 mL	1.1148 mL
	60 mM	0.0372 mL	0.1858 mL	0.3716 mL	0.9290 mL
	80 mM	0.0279 mL	0.1393 mL	0.2787 mL	0.6967 mL
	100 mM	0.0223 mL	0.1115 mL	0.2230 mL	0.5574 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

RAI-20

Epigenetics Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Orally Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Obesity Compound Library

Anti-Liver Cancer Compound Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Coagulation and Anti-coagulation Compound Library

Pain-Related Compound Library

Autoimmune Disease Compound Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

All JAK Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

RAI-20

Epigenetics Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Orally Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Obesity Compound Library

Anti-Liver Cancer Compound Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Coagulation and Anti-coagulation Compound Library

Pain-Related Compound Library

Autoimmune Disease Compound Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

All JAK Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

RAI-20 Related Classifications

Cat. No.: HY-181929